Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic epithelial tumor characterized by the presence of amyloid material within the tumor that can undergo calcification. CEOT affects individuals across a broad age range, typically between 20 and 60 years, with an average onset age of 40 years. However, it is extremely rare in children and adolescents. According to the literature, only 31 cases of CEOT in children and adolescents have been reported from 1971 to 2023, accounting for approximately 7 % of all CEOT cases. In the 2022 WHO classification of odontogenic tumors, CEOT is classified as a benign tumor, but it is inherently locally aggressive, capable of invading surrounding normal jawbone tissues, with a recurrence rate of 10-15 %. In this paper, we report a case of a 13-year-old male with a recurrence of CEOT in the mandible 43 months after surgery, covering clinical, imaging, histologic, immunohistochemical, and surgical aspects, and discuss its histopathologic features and treatment options.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.oraloncology.2025.107183 | DOI Listing |
Oral Oncol
January 2025
Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Jilin University, Changchun 130012, China. Electronic address:
Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic epithelial tumor characterized by the presence of amyloid material within the tumor that can undergo calcification. CEOT affects individuals across a broad age range, typically between 20 and 60 years, with an average onset age of 40 years. However, it is extremely rare in children and adolescents.
View Article and Find Full Text PDFOral Maxillofac Surg
January 2025
Department of Dentistry, State University of Maringá (UEM), Maringá, Brazil.
Background: Hybrid Odontogenic Tumors (HOT) are defined by the presence of two or more independent odontogenic tumors that originate from and affect the same maxillofacial site.
Methods: The present study is the first case report of a mandibular HOT consisting of Ameloblastoma, Calcifying Epithelial Odontogenic Tumor, and Ameloblastic Fibroma.
Case Report: A 37-year-old otherwise healthy male presented with the chief complaint of swelling in the right mandibular body.
Arch Dermatol Res
January 2025
Premier Dermatology, Ashburn, VA, USA.
Pilomatrix carcinoma (PC) is a rare malignant adnexal tumor originating from follicular matrix cells primarily impacting Caucasian males. This review provides a comprehensive analysis of scientific literature on PC through an exploration of 206 cases reported between 1980 and 2024. We discuss the epidemiology, clinical presentation, histopathology, and diagnostic challenges of PC, and explore various treatment methods for this rare malignancy as well as their associated outcomes.
View Article and Find Full Text PDFArch Oral Biol
November 2024
Laboratory of Histopathology and Immunohistochemistry, School of Dentistry, Universidade Federal do Pará, Belém, Pará, Brazil. Electronic address:
Objective: The study aimed to investigate the expression of hypoxia markers associated with invadopodia in glandular odontogenic cysts and to explore an association between this expression with the aggressive biological behaviour of this odontogenic cyst.
Design: Immunohistochemistry was employed to assess the expression of hypoxia-inducible factor 1 alpha (HIF-1α), notch homologous protein of the neurogenic locus 1 (NOTCH-1), disintegrin and metalloproteinase-12 (ADAM-12), and heparin-binding epidermal growth factor (HB-EGF) in 17 samples of glandular odontogenic cysts, 10 samples of calcifying odontogenic cysts, and 10 samples of dental follicles.
Results: The glandular odontogenic cyst samples exhibited increased expression of HIF-1α, NOTCH-1, ADAM-12 and HBEGF proteins compared with calcifying odontogenic cyst and dental follicle samples.
Int J Dermatol
December 2024
Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!